We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
1. Amendments to the Poison Standard in relation to New Chemical Entities (NCEs)
The NCEs listed below will be included in the new Poisons Standard that will come into effect on 1 October 2021.
Note
New text is shown as green, larger font, with a horizontal line above it.
1.1. Amifampridine
Recommendation
Schedule 4 - New Entry
AMIFAMPRIDINE.
Index - New Entry
AMIFAMPRIDINE
Schedule 4
Date of effect
1 October 2021
1.2. Belumosudil
Recommendation
Schedule 4 - New Entry
BELUMOSUDIL.
Appendix L - New Entry
BELUMOSUDIL.
Warning statements: 62 (Do not use if pregnant), 77(WARNING - May cause birth defects)
Index - New Entry
BELUMOSUDIL
Schedule 4
Appendix L
Date of effect
1 October 2021
1.3. Estetrol monohydrate
Recommendation
Schedule 4 - New Entry
ESTETROL MONOHYDRATE.
Index - New Entry
ESTETROL MONOHYDRATE
Schedule 4
Date of effect
1 October 2021
1.4. Finerenone
Recommendation
Schedule 4 - New Entry
FINERENONE.
Appendix L - New Entry
FINERENONE.
Warning statements: 67 (Do not use if pregnant or likely to become pregnant), 111 (Do not use if breastfeeding or planning to breastfeed).
Index - New Entry
FINERENONE
Schedule 4
Appendix L
Date of effect
1 October 2021
1.5. Fostemsavir
Recommendation
Schedule 4 - New Entry
FOSTEMSAVIR.
Index - New Entry
FOSTEMSAVIR
Schedule 4
Date of effect
1 October 2021
1.6. Inclisiran
Recommendation
Schedule 4 - New Entry
INCLISIRAN.
Index - New Entry
INCLISIRAN
Schedule 4
Date of effect
1 October 2021
1.7. Pegcetacoplan
Recommendation
Schedule 4 - New Entry
PEGCETACOPLAN.
Index - New Entry
PEGCETACOPLAN
Schedule 4
Date of effect
1 October 2021
1.8. Pegvaliase
Recommendation
Schedule 4 - New Entry
PEGVALIASE.
Index - New Entry
PEGVALIASE
Schedule 4
Date of effect
1 October 2021
1.9. Sacituzumab govitecan
Recommendation
Schedule 4 - New Entry
SACITUZUMAB GOVITECAN.
Index - New Entry
SACITUZUMAB GOVITECAN
Schedule 4
Date of effect
1 October 2021
1.10. Sotrovimab
Recommendation
Schedule 4 - New Entry
SOTROVIMAB.
Index - New Entry
SOTROVIMAB
Schedule 4
Date of effect
1 October 2021
1.11. Trastuzumab deruxtecan
Recommendation
Schedule 4 - New Entry
TRASTUZUMAB DERUXTECAN.
Appendix L - New Entry
TRASTUZUMAB DERUXTECAN.
Warning statements: 62 (Do not use if pregnant), 77(WARNING - May cause birth defects)
Index - New Entry
TRASTUZUMAB DERUXTECAN
Schedule 4
Appendix L
Date of effect
1 October 2021
1.12. Vericiguat
Recommendation
Schedule 4 - New Entry
VERICIGUAT.
Index - New Entry
VERICIGUAT
Schedule 4
Date of effect
1 October 2021
1.13. Zanubrutinib
Recommendation
Schedule 4 - New Entry
ZANUBRUTINIB.
Index - New Entry
ZANUBRUTINIB
Schedule 4
Date of effect
1 October 2021